Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Birtamimab - Prothena

Next Previous
Drug Profile

Birtamimab - Prothena

Alternative Names: NEOD-001

Latest Information Update: 22 Jan 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Neotope Biosciences; Onclave Therapeutics
  • Developer Prothena
  • Class Monoclonal antibodies
  • Mechanism of Action Amyloid fibril protein AL inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Amyloidosis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Amyloid light-chain amyloidosis

Most Recent Events

  • 09 Dec 2023 Pooled analysis adverse events data from a phase I to III trial in Light chain amyloidosis presented at the 65th American Society of Hematology Annual Meeting and Exposition (ASH-2023)
  • 12 Oct 2023 Prothena Biosciences initiates a Phase-III clinical trials in Amyloid light-chain amyloidosis (Treatment-naive) in Belgium (IV) (EudraCT2021-000037-14) (NCT04973137)
  • 16 Jan 2023 Efficacy data from a phase III VITAL trial in Systemic (AL) Amyloidosis in 64th American Society of Hematology (ASH-Hem-2022)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top